Prime Day Kicks Off With $150 Off This Impressive Eureka E20 Plus Robot Vac and Mop
This handy robot vacuum and mop would normally retail for around $450, but this deal has slashed that price by $150 for a limited time. The robot is even available in both black and white, so you can pick the one that best fits your home's aesthetic.
With summer now here, you've got better things to do than clean your own home, so this deal comes at the perfect time. The Eureka E20 Plus features a bagless, self-emptying design that can go for up to 45 days before you need to intervene. It also sports anti-tangle technology, which is a real bonus for those of us with furry friends.
Hey, did you know? CNET Deals texts are free, easy and save you money.
If your floors are a mix of carpet and hard surfaces, the built-in mopping feature will be of particular interest. The robot automatically raises the mop when a carpet is detected, so you won't wind up with a soggy mess. And with advanced LiDAR sensors ensuring accurate maps of your home are created, this thing won't get stuck or bump into your furniture as it goes.
Best Prime Day Robot Vacuum Deals
Check out our collection of top Prime Day robot vacuum deals so you can save time and money in addition to keeping your floors clean.
See Now
Why this deal matters
Nobody should be cleaning their own floors in 2025, and deals like this make it easier to employ a robot to do it without breaking the bank. This model automatically empties itself and can run for up to three hours before it has to return to the charging base for power. At this price, it's a no-brainer. Just make sure to order yours before this deal comes to a close.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Exact Sciences to acquire US rights for Freenome's blood-based CRC test
Freenome has entered an exclusive licence agreement with Exact Sciences, granting the latter the rights to commercialise Freenome's blood-based colorectal cancer (CRC) screening test in the US. Exact Sciences plans to accelerate the market adoption of the CRC blood test by leveraging its commercial infrastructure. Under the agreement, Exact Sciences will pay Freenome an upfront cash payment of $75m that is payable by this November. Freenome is set to receive up to an additional $700m, contingent upon reaching specific milestones related to its CRC screening tests. These milestones include a $100m payment upon receiving first-line approval from the Food and Drug Administration (FDA) for their inaugural test and another $100m for the approval of a subsequent, next-generation test that meets or exceeds certain performance criteria, such as a minimum of 19% advanced precancerous lesions (APL) sensitivity and 83% overall CRC sensitivity. However, should the performance fall below these benchmarks, the payment would be adjusted accordingly. Furthermore, Freenome could earn $500m if its test is classified as a first-line A or B test in the US Preventive Services Taskforce (USPSTF) guidelines or if it achieves certain payer-contracted coverage requirements. Again, a decreased payment is applicable if the test is included in the USPSTF guidelines as a second-line A or B test. Freenome could be entitled to obtain royalties that vary between 0% and 10%, depending on the profitability of the test, while also adhering to standard provisions for royalty stacking. However, if specific conditions are not fulfilled, Exact Sciences reserves the right to end the agreement. Exact Sciences noted that it is committed to investing $20m annually over three years in joint research and development to further utilise the technology. Freenome retains rights to its CRC blood test when combined with other cancer screening tests. The license agreement also includes a senior convertible note purchase by Exact Sciences, amounting to $50m, with a coupon rate of 5% due in 2030. Freenome's PREEMPT CRC Study, which involved nearly 49,000 adults at average risk, demonstrated the CRC test's ability to identify 81.1% of CRC, including 63.5% at stage one, and 13.7% of APL, with a specificity of 90.4%. Freenome is also working on an 'improved version' of the test, which has shown enhanced performance in detection rates, and plans to submit a supplemental premarket approval application to the FDA once final clinical validation data are available. In a recent development, Exact Sciences expanded its collaboration with private insurer Humana to make the Cologuard Plus test available to eligible Humana Medicare Advantage members as an in-network service across the US. "Exact Sciences to acquire US rights for Freenome's blood-based CRC test" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
NiCE Provides Webcast and Dial-in Details for its Second Quarter 2025 Results Teleconference
HOBOKEN, N.J., August 07, 2025--(BUSINESS WIRE)--NiCE (Nasdaq: NICE) will announce its second quarter 2025 results on Thursday, August 14, 2025, before the opening of the NASDAQ Stock Exchange. Later that day, management will host a conference call to discuss the results. 8:30 AM - Eastern1:30 PM - UK3:30 PM - Israel The call will be webcast live on the Company's website at Please register with the relevant link for either the webcast or dial-in on our "upcoming event page." Kind Regards,NiCE Investor Relations About NiCENiCE (NASDAQ: NICE) is transforming the world with AI that puts people first. Our purpose-built AI-powered platforms automate engagements into proactive, safe, intelligent actions, empowering individuals and organizations to innovate and act, from interaction to resolution. Trusted by organizations throughout 150+ countries worldwide, NiCE's platforms are widely adopted across industries connecting people, systems, and workflows to work smarter at scale, elevating performance across the organization, delivering proven measurable outcomes. Trademark Note: NiCE and the NiCE logo are trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE's marks, please see: View source version on Contacts Investor Relations Contact Marty Cohen, +1-551-256-5354, ir@ ETOmri Arens, +972-3-763-0127, ir@ CET Corporate Media Contact Christopher Irwin-Dudek, 201-561-4442, media@ ET Sign in to access your portfolio
Yahoo
14 minutes ago
- Yahoo
Historic transfer: Son Heung-min signs with Los Angeles until 2027
MLS: Son Heung-min joins Los Angeles FC for two seasons! Son Heung-min / @ After intense negotiations, the American club Los Angeles has officially announced the signing of South Korean superstar Son Heung-min from Tottenham. This transfer becomes the most expensive in Major League Soccer history. At 33 years old, Son has signed a contract running until the end of 2027. The American club reached an agreement with Tottenham to buy out the remainder of the player's contract for $26 million, surpassing the previous record held by Ivorian Emmanuel Lâté ($22 million). Tottenham expressed its gratitude to their Korean international on the platform (X): "We can never thank you enough, Sonny." This transfer marks the end of a decade at the "Spurs" for Son, who played 454 matches and scored 173 goals, highlighted by the Europa League triumph last May. Son's final match in Tottenham colors took place against Newcastle United, during a friendly played in South Korea on August 3, which ended in a 1-1 draw.
